Department of Medical Pharmacology, Medical Faculty, Van Yuzuncu Yıl University, Van, Turkey.
Department of Medical Biology, Medical Faculty, Van Yuzuncu Yıl University, Van, Turkey.
J Invest Surg. 2022 Jan;35(1):83-91. doi: 10.1080/08941939.2020.1824249. Epub 2020 Dec 15.
Gastric and esophageal cancers are 2 of the most prevalent cancer types worldwide. Polymorphisms in the genes that code the methylenetetrahydrofolate reductase (MTHFR) enzyme increase the formation of both cancer types. In this study, it was aimed to research the relationship between the existence of and polymorphisms in patients with gastric and esophageal cancer and the lifespans of patients.
This prospective study was performed at Van Yuzuncu Yil University. Included in the study were 30 patients with esophageal tumors, 70 patients with gastric tumors, and 61 healthy volunteers. From each of the patients, 5 mL of blood was drawn. DNA was isolated via kits with spin-column technology.
It was concluded that the risk of developing gastric cancer was 4.13 times higher in individuals who had the genotype of the polymorphism when compared to those who had the genotype, while the risk was 2.91 times higher in individuals who had the genotype when compared to those who had the genotype (P = 0.001, P = 0.027). Carriers of the genotype of the polymorphism had 2.89 times higher risk of developing esophageal cancer when compared to those who had the genotype (P = 0.033). It was determined that individuals who had the 1298 genotype were not at higher risk of developing esophageal cancer when compared to those with the genotype (P = 0.863). It was concluded that individuals who had the genotype of the polymorphism were not at higher risk of developing gastric and esophageal cancers when compared to those who had the genotype (P > 0.05). There was no difference in terms of the life spans of the patients with regards to the genotypes (P > 0.05).
The results showed that the polymorphism on the MTHFR gene can be a risk factor for gastric and esophageal cancer in eastern Turkey. These polymorphisms may have no effect on the life spans of the patients.
胃癌和食管癌是全球最常见的两种癌症类型。编码亚甲基四氢叶酸还原酶(MTHFR)酶的基因中的多态性会增加这两种癌症的发生。本研究旨在研究 MTHFR 基因上的 和 多态性的存在与胃癌和食管癌患者的生存时间之间的关系。
这项前瞻性研究在凡大学进行。研究纳入了 30 名食管肿瘤患者、70 名胃癌患者和 61 名健康志愿者。从每位患者抽取 5ml 血液。采用带有 spin-column 技术的试剂盒提取 DNA。
与携带 基因型的个体相比,携带 基因型的个体患胃癌的风险增加了 4.13 倍,而携带 基因型的个体患胃癌的风险增加了 2.91 倍(P=0.001,P=0.027)。与携带 基因型的个体相比,携带 基因型的个体患食管癌的风险增加了 2.89 倍(P=0.033)。携带 1298 基因型的个体患食管癌的风险并不高于携带 基因型的个体(P=0.863)。与携带 基因型的个体相比,携带 基因型的个体患胃癌和食管癌的风险没有增加(P>0.05)。患者的生存时间与基因型无关(P>0.05)。
研究结果表明,MTHFR 基因上的 多态性可能是土耳其东部胃癌和食管癌的一个危险因素。这些多态性可能对患者的生存时间没有影响。